AR087727A1 - Analogos del factor de liberacion de la hormona de crecimiento (grf) y sus usos - Google Patents
Analogos del factor de liberacion de la hormona de crecimiento (grf) y sus usosInfo
- Publication number
- AR087727A1 AR087727A1 ARP120101345A ARP120101345A AR087727A1 AR 087727 A1 AR087727 A1 AR 087727A1 AR P120101345 A ARP120101345 A AR P120101345A AR P120101345 A ARP120101345 A AR P120101345A AR 087727 A1 AR087727 A1 AR 087727A1
- Authority
- AR
- Argentina
- Prior art keywords
- ala
- absent
- leu
- arg
- ser
- Prior art date
Links
- 102000018997 Growth Hormone Human genes 0.000 title abstract 2
- 108010051696 Growth Hormone Proteins 0.000 title abstract 2
- 239000000122 growth hormone Substances 0.000 title abstract 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 abstract 6
- 102000038461 Growth Hormone-Releasing Hormone Human genes 0.000 abstract 5
- 239000000095 Growth Hormone-Releasing Hormone Substances 0.000 abstract 5
- 101710142969 Somatoliberin Proteins 0.000 abstract 5
- FUOOLUPWFVMBKG-UHFFFAOYSA-N 2-Aminoisobutyric acid Chemical compound CC(C)(N)C(O)=O FUOOLUPWFVMBKG-UHFFFAOYSA-N 0.000 abstract 4
- QUOGESRFPZDMMT-UHFFFAOYSA-N L-Homoarginine Natural products OC(=O)C(N)CCCCNC(N)=N QUOGESRFPZDMMT-UHFFFAOYSA-N 0.000 abstract 4
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 abstract 4
- QUOGESRFPZDMMT-YFKPBYRVSA-N L-homoarginine Chemical compound OC(=O)[C@@H](N)CCCCNC(N)=N QUOGESRFPZDMMT-YFKPBYRVSA-N 0.000 abstract 4
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 abstract 4
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 abstract 3
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 abstract 2
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 abstract 2
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 abstract 2
- 229960003104 ornithine Drugs 0.000 abstract 2
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 abstract 1
- SXGMVGOVILIERA-NFJMKROFSA-N (2s)-2,3-diaminobutanoic acid Chemical compound CC(N)[C@H](N)C(O)=O SXGMVGOVILIERA-NFJMKROFSA-N 0.000 abstract 1
- QNAYBMKLOCPYGJ-UWTATZPHSA-N D-alanine Chemical compound C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 abstract 1
- ODKSFYDXXFIFQN-SCSAIBSYSA-N D-arginine Chemical compound OC(=O)[C@H](N)CCCNC(N)=N ODKSFYDXXFIFQN-SCSAIBSYSA-N 0.000 abstract 1
- OGNSCSPNOLGXSM-VKHMYHEASA-N L-2,4-diaminobutyric acid Chemical compound NCC[C@H](N)C(O)=O OGNSCSPNOLGXSM-VKHMYHEASA-N 0.000 abstract 1
- 125000000998 L-alanino group Chemical group [H]N([*])[C@](C([H])([H])[H])([H])C(=O)O[H] 0.000 abstract 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 abstract 1
- UKAUYVFTDYCKQA-VKHMYHEASA-N L-homoserine Chemical compound OC(=O)[C@@H](N)CCO UKAUYVFTDYCKQA-VKHMYHEASA-N 0.000 abstract 1
- 239000000556 agonist Substances 0.000 abstract 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 230000028327 secretion Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/60—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/25—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Endocrinology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161477775P | 2011-04-21 | 2011-04-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR087727A1 true AR087727A1 (es) | 2014-04-16 |
Family
ID=47021786
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP120101345A AR087727A1 (es) | 2011-04-21 | 2012-04-19 | Analogos del factor de liberacion de la hormona de crecimiento (grf) y sus usos |
Country Status (10)
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013190520A2 (en) | 2012-06-22 | 2013-12-27 | The General Hospital Corporation | Gh-releasing agents in the treatment of vascular stenosis and associated conditions |
| EP3445778B1 (en) | 2016-04-19 | 2020-07-15 | Griffon Pharmaceuticals International SA | Pegylated bioactive peptides and uses thereof |
| KR20230035600A (ko) * | 2020-07-05 | 2023-03-14 | 쎄러테크놀로지스 인코포레이티드 | Ghrh 유사체의 저-용량 약제학적 조성물 및 이들의 용도 |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4518586A (en) | 1983-01-13 | 1985-05-21 | The Salk Institute For Biological Studies | GRF Analogs III |
| US4617149A (en) | 1983-09-21 | 1986-10-14 | Eli Lilly And Company | Growth hormone release factor analogs |
| US4622312A (en) | 1984-09-24 | 1986-11-11 | Hoffmann-La Roche Inc. | Growth hormone releasing factor analogs |
| US4734399A (en) * | 1985-08-06 | 1988-03-29 | Hoffmann-La Roche Inc. | Growth hormone releasing factor analogs |
| US4801456A (en) | 1987-07-09 | 1989-01-31 | International Minerals & Chemical Corp. | Growth hormone-releasing factor analogs |
| ATE106895T1 (de) * | 1987-09-18 | 1994-06-15 | Hoffmann La Roche | Zyklische grf-analoga. |
| IL97885A0 (en) * | 1990-04-24 | 1992-06-21 | Lilly Co Eli | Growth hormone releasing factor analogs |
| WO1992018531A1 (en) | 1991-04-09 | 1992-10-29 | F. Hoffmann-La Roche Ag | Growth hormone releasing factor analogs |
| US5262519A (en) | 1991-05-15 | 1993-11-16 | The Salk Institute For Biological Studies | GRF analogs XI |
| JPH11503454A (ja) | 1995-04-14 | 1999-03-26 | ジ アドミニストレイターズ オブ ザ チューレン エデュケイショナル ファンド | 成長ホルモン放出因子の類似体 |
| ES2163020T3 (es) | 1995-05-26 | 2002-01-16 | Theratechnologies Inc | Analogos quimericos de factor liberador de hormona de crecimiento (grf) de cuerpo graso, provistos de mayor potencia biologica. |
| TW432073B (en) * | 1995-12-28 | 2001-05-01 | Pfizer | Pyrazolopyridine compounds |
| EP0922446A1 (en) | 1997-12-03 | 1999-06-16 | Applied Research Systems Ars Holding N.V. | Solution-phase site-specific preparation of GRF-PEG conjugates |
| US6057422A (en) | 1998-11-25 | 2000-05-02 | The Administrators Of The Tulane Educational Fund | Antagonistic analogs of GH-RH inhibiting IGF-I and -II |
| US7256258B2 (en) | 2000-10-05 | 2007-08-14 | Ares Trading S.A. | Regioselective liquid phase pegylation |
| WO2002062844A2 (en) | 2001-02-02 | 2002-08-15 | Conjuchem Inc. | Long lasting growth hormone releasing factor derivatives |
| CZ305160B6 (cs) * | 2001-06-08 | 2015-05-27 | Ipsen Pharma S.A.S. | Chimérické somatostatin-dopaminové analogy |
| RU2005111253A (ru) | 2002-09-18 | 2005-11-20 | Сантр Оспиталье Де Л` Юниверсите Де Монреаль (Схюм) (Ca) | Аналоги ghrh |
| WO2004105789A1 (en) | 2003-05-29 | 2004-12-09 | Theratechnologies Inc. | Grf analog compositions and their use |
| TW200517400A (en) | 2003-08-05 | 2005-06-01 | Univ Tulane | Antagonistic analogs of GH-RH (2003) |
| US7893025B2 (en) | 2003-10-20 | 2011-02-22 | Theratechnolgies Inc. | Use of growth hormone releasing factor analogs in treating patients suffering from wasting |
| JP2008516994A (ja) | 2004-10-20 | 2008-05-22 | セラテクノロジーズ、インコーポレイテッド | 成長ホルモン分泌促進因子およびその使用 |
| US8021859B2 (en) | 2005-03-15 | 2011-09-20 | Allergan, Inc. | Modified clostridial toxins with altered targeting capabilities for clostridial toxin target cells |
| WO2009009727A2 (en) | 2007-07-12 | 2009-01-15 | Akela Pharma Srl | Ghrh analogs and therapeutic uses thereof |
| US20110021429A1 (en) | 2007-10-01 | 2011-01-27 | Pierrette Gaudreau | Renoprotection by growth hormone-releasing hormone and agonists |
| EP2421548A4 (en) | 2009-04-20 | 2012-09-26 | Theratechnologies Inc | USE OF (HEXENOYL TRANS-3) HGRF (1-44) NH2 AND SIMVASTATIN IN COMBINED TREATMENT |
-
2012
- 2012-04-17 BR BR112013027150A patent/BR112013027150A2/pt not_active IP Right Cessation
- 2012-04-17 CA CA2833434A patent/CA2833434A1/en not_active Abandoned
- 2012-04-17 EP EP12774217.9A patent/EP2699591A4/en not_active Withdrawn
- 2012-04-17 WO PCT/CA2012/050242 patent/WO2012142706A1/en active Application Filing
- 2012-04-17 JP JP2014505470A patent/JP6113144B2/ja not_active Expired - Fee Related
- 2012-04-17 MX MX2013012259A patent/MX2013012259A/es active IP Right Grant
- 2012-04-17 KR KR1020137030657A patent/KR20140027284A/ko not_active Withdrawn
- 2012-04-17 US US13/448,660 patent/US8361964B2/en not_active Expired - Fee Related
- 2012-04-17 CN CN201280024235.3A patent/CN103547591A/zh active Pending
- 2012-04-19 AR ARP120101345A patent/AR087727A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN103547591A (zh) | 2014-01-29 |
| EP2699591A4 (en) | 2014-05-07 |
| MX2013012259A (es) | 2013-11-22 |
| JP2014515751A (ja) | 2014-07-03 |
| CA2833434A1 (en) | 2012-10-26 |
| EP2699591A1 (en) | 2014-02-26 |
| US20120270784A1 (en) | 2012-10-25 |
| BR112013027150A2 (pt) | 2017-06-06 |
| KR20140027284A (ko) | 2014-03-06 |
| JP6113144B2 (ja) | 2017-04-12 |
| US8361964B2 (en) | 2013-01-29 |
| WO2012142706A1 (en) | 2012-10-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2704651C (en) | Use of melanocortins to treat insulin sensitivity | |
| AR124918A2 (es) | Proteínas insecticidas nuevas y métodos de uso | |
| AR105816A2 (es) | Derivados de exendina-4 funcionalizada | |
| AR070119A1 (es) | Derivados de insulina con perfil tiempo / accion extremadamente retardado | |
| JP2013518115A5 (enrdf_load_stackoverflow) | ||
| NI201200134A (es) | Polipéptidos agonistas que se enlazan a dr5 | |
| JP2015528795A5 (enrdf_load_stackoverflow) | ||
| AR078950A1 (es) | Peptido agonista de la guanilato ciclasa c (gc-c) util para tratamientos de trastornos gastrointestinales | |
| RS53505B1 (en) | OXYTOMODULIN PEPTIDE ANALOG | |
| AR099976A1 (es) | Agonistas peptídicos duales de los receptores de glp-1 / glucagón derivados de la exendina-4 | |
| NZ597580A (en) | Polypeptides selective for alpha.v.beta.3 integrin conjugated with a variant of human serum albumin (hsa) and pharmaceutical uses thereof | |
| CO6260151A2 (es) | Peptido de cdh3 y agente medicinal que comprende al mismo | |
| CO6541617A2 (es) | Método para tratar la insuficiencia cardíaca con péptidos tipo estrescopina | |
| AR068020A1 (es) | Terapia combinada para el cancer de pancreas usando un peptido antigenico y un agente quimioterapeutico | |
| US20130331324A1 (en) | Use of melanocortins to treat dyslipidemia | |
| Garrett et al. | The role of parathyroid hormone and insulin-like growth factors in hematopoietic niches: physiology and pharmacology | |
| AR087727A1 (es) | Analogos del factor de liberacion de la hormona de crecimiento (grf) y sus usos | |
| AR088727A1 (es) | Peptidos ciclicos con actividad antineoplasica y antiangiogenica | |
| Jankowski et al. | Oxytocin in the heart regeneration | |
| ES2541364T3 (es) | Péptido | |
| Kono et al. | Identification and immunoregulatory function of neuromedin U (Nmu) in the Japanese pufferfish Takifugu rubripes | |
| AR098732A1 (es) | Un proceso para la preparación de una composición de proteínas pegiladas | |
| Naono-Nakayama et al. | Pharmacological characteristics of endokinin C/D-derived peptides in nociceptive and inflammatory processing in rats | |
| HK1221147B (en) | Use of melanocortins to treat insulin sensitivity | |
| HK1146242B (en) | Use of melanocortins to treat insulin sensitivity |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |